araag2/HINT huggingface dataset:
Clinical trial NCT00476645 (phase 2, status: completed)
Conditions: prostatic neoplasms, prostate cancer
ICD codes: B38.81, N42.31, Z87.430, N40.0, N40.1, C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: fulvestrant
SMILES: [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Must give signed written informed consent

          -  Must be of age 18 years or older

          -  Histologically confirmed adenocarcinoma of the prostate

          -  Must be currently receiving LHRH agonists and have castrate levels of testosterone or
             have had an orchiectomy

          -  Must have had rise in PSA despite anti-androgen withdrawal

          -  Must exhibit two consecutive rises in PSA after the last hormonal manipulation

          -  Minimum PSA > 5mg/dL

          -  KPS > 80%

          -  Up to one prior chemotherapy treatments allowed

          -  Life expectancy of greater than 6 months

        Exclusion Criteria:

          -  Concomitant hormonal therapy other than an LHRH

          -  Noncompliance

          -  Platelets less than 100 x 10e9 /L

          -  International normalization ratio (INR) greater than 1.6

          -  Total bilirubin greater than 1.5 x ULRR

          -  ALT or AST greater than 2.5 x ULRR if no demonstrable liver metastases or greater than
             5.0 x ULRR in presence of liver metastases

          -  History of bleeding diathesis (ie, disseminated intravascular coagulation [DIC],
             clotting factor deficiency)

          -  History of long-term anticoagulant therapy (other than antiplatelet therapy)

          -  History of hypersensitivity to active or inactive excipients of fulvestrant (ie,
             castor oil or Mannitol)
Clinical trial NCT00321087 (phase 2, status: terminated)
Conditions: essential tremor
ICD codes: G25.0
Drugs: t2000, t2000, t2000
SMILES: COCN1C(=O)N(COC)C(=O)C(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1, COCN1C(=O)N(COC)C(=O)C(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1, COCN1C(=O)N(COC)C(=O)C(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1
Reason stopped: 
    slow enrollment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed essential tremor by NIH criteria

          -  Significant functional activity limitation due to ET

          -  Patients who have failed, are inadequately treated or cannot tolerate alternative
             treatments for ET as well as treatment naïve patients who have considered but declined
             alternative treatment

        Exclusion Criteria:

          -  Patients adequately controlled without side effects on a current ET treatment

          -  Pregnant patients or patients who may become pregnant during the study

          -  Patients with other medical conditions that may cause tremor, such as Parkinson's
             disease or active hyperthyroidism

          -  Patients taking medications that might produce tremor or interfere with the evaluation
             of tremor such as CNS-stimulants or beta-blockers

          -  Patients who must take medications that alter liver metabolism as well as patients
             with liver disease or coagulation disorders

          -  Patients with seizure disorders

          -  Patients with a history of allergy or hypersensitivity reaction to barbiturates or
             other related medications, such as phenobarbital or phenytoin

          -  Patient with significant general medical or clinical laboratory abnormalities
Clinical trial NCT00577668 (phase 2, status: withdrawn)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: melphalan, velcade, thalidomide, dexamethasone
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Reason stopped: 
    poor accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  History of histologically documented MM with relapsed or progressive disease after
             either scheduled tandem or one autologous transplantation.

          -  Patient has measurable disease in which to capture response.

          -  Performance status of 2 as per Zubroid scale, unless PS of 3-4 based solely on bone
             pain.

          -  Patients must have a platelet count 75,000/μL, and an ANC of at least 1,000/μL.

          -  Patients must have adequate renal function defined as serum creatinine < 2.5 mg/dL.

          -  Patients must have adequate hepatic function defined as serum transaminases and direct
             bilirubin < 2 x the upper limit of normal.

          -  Pregnant or nursing women may not participate. Women of childbearing potential must
             have a negative pregnancy documented within one week of registration. Women of
             reproductive potential may not participate unless they have agreed to use an effective
             contraceptive method.

          -  Male or female adults of at least 18 years of age.

          -  Patients must have signed an IRB-approved written informed consent form and
             demonstrate willingness to meet follow-up schedule and study procedure obligations.

        Exclusion Criteria:

          -  Chemotherapy or radiotherapy received within the previous 2 weeks.

          -  Significant neurotoxicity, defined as grade > 2 neurotoxicity per NCI Common Toxicity
             Criteria (See Appendix).

          -  Platelet count < 75,000/mm3, or ANC < 1,000/μl.

          -  Clinically significant hepatic dysfunction as noted by bilirubin or AST > 3 times the
             upper normal limit or clinically significant concurrent hepatitis.

          -  New York Hospital Association (NYHA) Class III or Class IV heart failure.

          -  Myocardial infarction within the last 6 months.

          -  Uncontrolled, active infection requiring IV antibiotics.

          -  Patients with a history of treatment for clinically significant ventricular cardiac
             arrhythmias.

          -  Poorly controlled hypertension, diabetes mellitus, or other serious or psychiatric
             illness that could potentially interfere with the completion of treatment according to
             this protocol.

          -  Pregnant or potential for pregnancy. Women of childbearing potential will have a
             pregnancy test at screening, and will be required to use a medically approved
             contraceptive method.

          -  Breast-feeding women may not participate.
Clinical trial NCT01194427 (phase 2, status: terminated)
Conditions: stage i breast cancer, stage ii breast cancer, stage iii breast cancer, invasive breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: vorinostat and tamoxifen
SMILES: CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
Reason stopped: 
    difficulty meeting patient accrual goals
  
Eligibility criteria:

        Inclusion Criteria:

          -  Stage I-III invasive breast cancer

          -  Awaiting surgery or neoadjuvant treatment

          -  ECOG performance status 0, 1 or 2

          -  Adequate organ function

          -  Prior use of hormone contraception or replacement therapy must have been discontinued
             at least 30 days prior to diagnostic biopsy (unless participant is willing to undergo
             an additional biopsy for the study)

        Exclusion Criteria:

          -  Prior or current treatment of any kind for the current breast cancer

          -  Current use of any other investigational drugs

          -  Uncontrolled or active infection, congestive heart failure, cardiac arrythmia, or
             psychiatric illness
Clinical trial NCT01107093 (phase 2, status: completed)
Conditions: contraception
ICD codes: Z92.0, Z30.012, Z30.09
Drugs: cdb-2914 (ulipristal acetate), placebo
SMILES: CN(C)C1=CC=C(C=C1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Women of good general health aged 18 - 35 years

          -  Not at risk of pregnancy

          -  Regular menstrual cycles of 24-35 days duration

          -  Not pregnant

          -  Intact uterus and ovaries

          -  Haemoglobin ≥ 11 g/dl

          -  Normal laboratory tests and normal TSH

          -  Willing to abstain from any use of hormonal contraception until study completion

          -  No current use of hormonal contraception and having had at least one complete
             menstrual cycle (2 menses) since termination of previous hormonal contraception

          -  Had at least one complete menstrual cycle (2 menses) following delivery, miscarriage
             or induced abortion

          -  Able to give voluntary, written informed consent, and agreeing to observe all study
             requirements for 5 complete menstrual cycles

        Exclusion Criteria:

          -  Current participation in any other trial of an investigational medicine

          -  Known hypersensitivity to the ingredients of the test active substances or excipients

          -  Suspected hyperplasia or carcinoma of the endometrium

          -  Current pregnancy as confirmed by positive serum beta-hCG at screening

          -  Desire to get pregnant before the planned end of the study participation

          -  Currently breastfeeding

          -  Abnormal Pap smear

          -  Cancer (past history of any carcinoma or sarcoma)

          -  Known or suspected alcoholism or drug abuse

          -  Abnormal thyroid status

          -  Body mass index > 32

          -  Current use of hormonal contraception

          -  Use of hormonal emergency contraception since last menstrual period

          -  Severe asthma insufficiently controlled by oral glucocorticoids

          -  Hereditary galactose intolerance, Lapp lactase deficiency, or glucose-galactose
             malabsorption
Clinical trial NCT00068744 (phase 2/phase 3, status: terminated)
Conditions: anal cancer
ICD codes: C21.1, C44.500, C44.590, D12.9, C21.8
Drugs: cisplatin, fluorouracil, mitomycin c
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CO[C@]12[C@H]3N[C@H]3CN1C1=C([C@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O
Reason stopped: 
    low accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed squamous cell anal carcinoma

               -  Keratinizing or non-keratinizing

               -  The following stages are eligible:

                    -  T2, N0, M0 with maximum tumor diameter at least 4 cm

                    -  T3-T4, N0, M0

                    -  Any T, N1-N3, M0

          -  Tumor located in the anal canal OR in the anal margin and infiltrating the anal canal

          -  No primary adenocarcinoma of the anus

          -  Measurable disease

        PATIENT CHARACTERISTICS:

        Age

          -  18 to 75

        Performance status

          -  WHO 0-1

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Granulocyte count greater than 2,000/mm^3

          -  Platelet count greater than 100,000/mm^3

        Hepatic

          -  Not specified

        Renal

          -  Creatinine less than 1.4 mg/dL

        Cardiovascular

          -  No grade I angina pectoris with clinical symptoms within the past 3 months

          -  No grade II-IV angina pectoris within the past 3 months

          -  No stage II or greater distal arteritis

        Other

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No other prior malignancy except adequately treated basal cell skin cancer or
             carcinoma in situ of the cervix

          -  No psychological, familial, sociological, or geographical condition that would
             preclude study compliance and follow-up

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  No other concurrent chemotherapy

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  No other concurrent radiotherapy

        Surgery

          -  No prior colostomy

        Other

          -  No prior treatment for anal cancer
Clinical trial NCT00420641 (phase 2, status: completed)
Conditions: depressive disorder
ICD codes: F25.1, F33.0, F33.1, F33.9, F32.0, F32.1, F32.9
Drugs: gsk372475, paroxetine
SMILES: COC[C@H]1[C@H]2CC[C@@H](C[C@@H]1C1=CC=C(Cl)C(Cl)=C1)N2C, FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
Eligibility criteria:

        Inclusion criteria:

          -  Major depressive episode (MDE) associated with Major Depressive Disorder (DSM-IV-TR
             criteria)

          -  Duration of current episode is at least 12 weeks duration and less than 2 years

          -  Symptoms of decreased energy, pleasure, and interest

          -  Female subjects who agree to use acceptable methods of birth control throughout the
             study

        Exclusion criteria:

          -  Current diagnosis of Panic Disorder, or symptoms of generalized anxiety or panic
             attacks that could interfere with their ability to complete the trial

          -  Symptoms of MDE better accounted for by another diagnosis

          -  Diagnosis of panic disorder / attacks, generalised anxiety, borderline or antisocial
             personality disorder, dementia, anorexia nervosa / bulimia (within 6 months of
             screening), bipolar disorder, schizophrenia or any other psychotic disorder(s).

          -  Started psychotherapy within 3 months prior to the Screening

          -  Received electroconvulsive therapy or transcranial magnetic stimulation within 6
             months prior to screening

          -  Received psychoactive drugs within 4 weeks of randomization

          -  Positive urine drug screen or positive blood alcohol

          -  Suicidal risk or has had any previous suicide attempt, a family history of suicide
             attempt

          -  Positive pregnancy test

          -  History of seizure disorder, myocardial infarction (< 1yr), or unstable medical
             condition

          -  Failed to respond to an adequate course of pharmacotherapy of at least 2 different
             antidepressants
Clinical trial NCT01201317 (phase 2, status: completed)
Conditions: neuropathic pain
ICD codes: E85.1, E85.0, N31.0, N31.1, N31.2, E10.610, E11.610
Drugs: azd2423, azd2423, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Provision of signed informed consent form

          -  Males and female of non-child bearing potential patients aged 18 to 80 years

          -  Patients with neuropathic pain due to painful diabetic polyneuropathy.

        Exclusion Criteria:

          -  Other pain that may confound assessment of neuropathic pain

          -  History of treatment failure with more than three adequate trials of medication for
             neuropathic pain

          -  Central neuropathic pain conditions (caused by Central Nervous System injury/disease,
             eg. Stroke)
Clinical trial NCT00258622 (phase 2, status: completed)
Conditions: pain
ICD codes: N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: ns1209, lidocaine
SMILES: OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Age >18 years

          -  Neuropathic pain and allodynia after a peripheral nerve injury (VAS >= 4)

        Exclusion Criteria:

          -  Patients who cannot cooperate and do no understand Danish

          -  Fertile women

          -  Clinically significant abnormality or disease

          -  Drug and alcohol abuse

          -  Clinically abnormal ECG

          -  Hypersensitivity to any of the treatments

          -  Patients in treatment with cimetedin, antidepressants, antipsychotics, antiepileptics
             except gabapentin, anticoagulants, Na channel blockers and beta blockers

          -  Patients who have previously been treated in a NS1209 study

          -  Patients treated with an investigational drug
Clinical trial NCT01171313 (phase 2, status: completed)
Conditions: parkinson's disease
ICD codes: G20
Drugs: xp21279 and carbidopa (experimental), sinemet (comparator), placebo for xp21279 and carbidopa, placebo for sinemet
SMILES: C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O, C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O, C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Subjects must have predictable motor fluctuations of the wearing off type, defined by
             meeting the following criteria based on the on/off diaries recorded over 3 days in the
             Screening Period:

               -  Wearing-off in at least half (50%) of inter-dose intervals between the first and
                  the last daily doses averaged over the 3 diary days, and

               -  An average daily "off" time of 2 hours after the first "on" of the day through
                  awake time up to midnight.

          2. Subjects must be on one of the following stable QID or 5 times daily regimens for at
             least 4 weeks prior to Screening: Sinemet® or carbidopa-levodopa, with a total daily
             dose ranging from 400 mg to 1000 mg of levodopa

        Exclusion Criteria:

          1. History, signs, or symptoms suggesting the diagnosis of secondary or atypical
             Parkinsonism.

          2. Subject has moderately or severely disabling dyskinesias for greater than 25% of the
             waking day

          3. Subjects who have significant neurological symptoms not accounted for by Parkinson's
             disease

          4. Subjects who are taking Sinemet® CR, Parcopa®, concomitant COMT inhibitors (i.e.,
             entacapone or tolcapone), Stalevo®, or benserazide containing levodopa preparations
             Madopar® or Prolopa®.
Clinical trial NCT00296374 (phase 2, status: completed)
Conditions: diabetes mellitus
ICD codes: P70.2, O24.92, Z83.3, E10.65, E10.9, E11.65, E11.9
Drugs: rosuvastatin, rosuvastatin, atorvastatin
SMILES: CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O, CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  hyperlipidemia

          -  urinary protein

          -  diabetes

        Exclusion Criteria:

          -  previous rosuvastatin treatment < 6 months prior to Visit 1

          -  statin intolerance

          -  severe hypertension
Clinical trial NCT01192971 (phase 2, status: completed)
Conditions: advanced hepatocellular carcinoma
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: apatinib
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologic confirmed advanced hepatocellular carcinoma

          -  Life expectancy of more than 3 months.

          -  ECOG performance scale 0 - 2.

          -  No cirrhosis with child -pugh score A

          -  At least one measurable lesion (larger than 10 mm in diameter by spiral CT scan.

          -  Adequate hepatic, renal, heart, and hematologic functions (platelets > 90 × 109/L,
             neutrophil > 1.5 × 109/L, serum creatinine ≤ 1.5mg/dl, total bilirubin within upper
             limit of normal(ULN), and serum transaminase≤2.5×the ULN).

          -  signed and dated informed consent.Willingness and ability to comply with scheduled
             visits, treatment plans, laboratory tests, and other study procedure.

        Exclusion Criteria:

          -  Pregnant or breastfeeding women

          -  History of any second malignancies within 3 years except cured basal cell carcinoma of
             skin and carcinoma in-situ of uterine cervix

          -  Any factors that influence the usage of oral administration

          -  Evidence of CNS metastasis

          -  Intercurrence with one of the following: hypertension, coronary artery disease,
             arrhythmia and heart failure

          -  Receiving the therapy of thrombolysis or anticoagulation

          -  Abuse of alcohol or drugs

          -  Less than 4 weeks from the last clinical trial

          -  Disability of serious uncontrolled intercurrence infection.

          -  Treatment with potent CYP3A4 inhibitors and inducer with 7 and 12 days respectively,
             prior to study drug administration.
Clinical trial NCT00204568 (phase 2, status: unknown status)
Conditions: sarcoma, soft tissue
ICD codes: C46.1
Drugs: adriamycin, trofosfamide
SMILES: COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, ClCCN(CCCl)P1(=O)OCCCN1CCCl
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically established metastatic (N+ or M1 = stage IV) or non-resectable soft
             tissue sarcoma·

          -  Grading II/III (Guillou et al. J Clin Oncol 1997)

          -  At least 1 measurable tumor parameter according to RECIST criteria

          -  Evidence of progression or primary manifestation (except osseous metastases and
             pleural effusion)

          -  No previous radiation therapy of the only measurable lesion

          -  No previous chemotherapy for metastatic disease; previous adjuvant chemotherapy is
             permitted if there was no progression of the disease within a period of 6 months

          -  Patients aged 60 years and beyond

          -  Written patient informed consent

          -  ECOG Status 0-2

          -  Granulocytes >= 2 x 10**9/l and thrombocytes >= 100 x 10**/l

          -  Serum creatinine, bilirubin < 1.5 times the upper limit of normal value, albumin > 25
             g/l

          -  No severe comorbidity including psychosis or any previous history of uncontrolled
             cardiovascular disease

          -  Normal left-ventricular function by echocardiography or MUGA scan

          -  No symptomatic CNS metastases

          -  Willingness to receive regular follow-up examinations

        Exclusion Criteria:

          -  Histological grading of malignancy: G I

          -  Histology of gastrointestinal stromal tumor, chondrosarcoma, uterine stromal sarcoma,
             mesothelioma, neuroblastoma, osteosarcoma, Ewing´s sarcoma/PNET, desmoplastic round
             cell tumor, embryonal rhabdomyosarcoma, alveolar soft tissue sarcoma

          -  Less than 5 years free of secondary malignancy except adequately treated carcinoma in
             situ (CIS) of the cervix, the bladder urothelium, basal cell carcinoma, or adenoma of
             the colon including pTIS, pTIN